Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.

Laura Molenaar-KuijstenBart Albertus Wilhelmus JacobsSophie Alberdine KurkAnne Maria MayThomas Petrus Catharina DorloJacob Hendrik BeijnenNeeltje SteeghsAlwin Dagmar Redmar Huitema

Published in: Cancer medicine (2021)

No alterations in PK of capecitabine and the active and toxic metabolite 5-FU were observed in patients with a low SMM. Therefore, the previously identified increased toxicity and shorter survival in patients with a low SMM, could not be explained by changes in pharmacokinetic characteristics of capecitabine and metabolites.

Keyphrases

phase ii study
locally advanced
metastatic breast cancer
phase iii
ms ms
oxidative stress
squamous cell carcinoma
randomized controlled trial
clinical trial
radiation therapy
free survival
double blind
placebo controlled